
    
      This study was a randomized, double-blind, placebo-controlled, phase III study with 2
      parallel arms in adults and adolescents with HDM-associated allergic rhinitis (AR) for at
      least one year.

      The primary objective was to assess the efficacy of STG320 sublingual tablets at a daily
      dosage of 300 IR when administered for 12 months to adults and adolescents with
      HDM-associated AR. The primary efficacy variable was the average Total Combined Score.
    
  